Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TX000045
TX45 · 2 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| TX000045 300 mg | EXPERIMENTAL | Participants will receive subcutaneous (SC) injection of TX000045 at a dose of 300 milligrams (mg) every 4 weeks (Q4W) from Week 1 up to Week 13. |
| Name | Type | Description |
|---|---|---|
| TX000045- Dose A | DRUG | The participants will receive a subcutaneous injection of Dose A of TX000045 every 2 weeks for 24 weeks. |
| TX000045- Dose B | DRUG | The participants will receive subcutaneous injection of Dose B of TX000045 every 4 weeks for 24 weeks where they will alternate between TX000045 and placebo every 2 weeks. |
| Placebo | DRUG | The participants will receive a subcutaneous injection of placebo every 2 weeks for 24 weeks. |
| TX000045 | DRUG | Subcutaneous Injection. |
Inclusion Criteria: * Confirmed diagnosis of ILD based on imaging: chest computed tomography (CT) performed within the past 12 months with fibrotic lung disease (greater than or equal to (\>=) 10 percent (%) lung parenchyma with fibrosis) consistent with idiopathic interstitial pneumonia, ILD in as...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 5 | PHASE3 | selexipag, Macitentan |
| Merck & Co., Inc. | MRK | 8 | PHASE3 | Sotatercept, Riociguat, Frespaciguat |
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag, Tyvaso (treprostinil) |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606, LIQ861 Treprostinil, LIQ861 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | Levosimendan (TNX-103) |
| Inhibikase Therapeutics, Inc. | IKT | 2 | PHASE3 | IKT-001 |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Tectonic Therapeutic Inc | TECX | 2 | PHASE2 | TX45 |
| Gossamer Bio, Inc. | GOSS | 1 | PHASE3 | Seralutinib |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| IRulya Therapeutics Inc. | IRLA | 1 | PHASE2 | LAM-001 |
| GSK plc Sponsored ADR | GSK | 2 | PHASE1 | HS235 |
TX45 is an investigational small molecule drug being developed by Tectonic Therapeutic, Inc. (ticker TECX) for pulmonary hypertension. It is in Phase 2 clinical development. TX45 is also known as TX000045 and TX000045-Dose A. It has not been approved by the FDA and remains under clinical study.
TX45 is being studied for pulmonary hypertension, including pulmonary hypertension due to interstitial lung disease and pulmonary hypertension secondary to heart failure with preserved ejection fraction. Both are forms of pulmonary hypertension in which elevated blood pressure in the lung arteries complicates underlying heart or lung disease.
TX45 is being developed by Tectonic Therapeutic, Inc., which trades under the ticker TECX. Tectonic Therapeutic is the sponsor of the clinical program studying TX45 in pulmonary hypertension.
TX45 is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. Two Phase 2 trials have been registered, one currently recruiting and one completed, with a combined planned enrollment of 205 participants.
TX45 is being studied in two Phase 2 trials. NCT07473700 is recruiting 25 participants with pulmonary hypertension due to interstitial lung disease across the United States, Poland, Romania, Serbia, South Korea, and Spain. NCT06616974, the APEX study, is recruiting 180 participants with pulmonary hypertension secondary to heart failure with preserved ejection fraction.
Yes. TX45 is the same drug as TX000045 and TX000045-Dose A. These are alternative names for the same investigational small molecule developed by Tectonic Therapeutic for pulmonary hypertension, so search results under any of these names refer to the same Phase 2 program.